NEW MED FOR ALZHEIMER’S?
ANCHOR LEAD: A NEW MEDICINE MAY INTERRUPT THE PROCESS THAT LEADS TO ALZHEIMER’S DISEASE, ELIZABETH TRACEY REPORTS
An aberrant protein called beta amyloid is thought to be at least one of the culprits in the development of Alzheimer’s disease. Now an anti-inflammatory medication called tarenflurbil, currently in phase 2 trials, may interrupt the production of beta amyloid and slow or halt disease progression, as reported in the Lancet. Constantine Lyketsos, an Alzheimer’s disease expert at Johns Hopkins, explains..
LYKETSOS: The amyloid hypothesis really says that you get this accumulation of this beta amyloid protein after you’ve misprocessed the APP molecule, and that by getting this accumulation you slowly kill off the synapses. The synapses slowly die off, creating tangles inside the nerve cells. Eventually the nerve cells die, and slowly the brain rots and degenerates. :24
The trial shows that the medication only helps people in the early stages of the Alzheimer’s disease. I’m Elizabeth Tracey reporting